A multicenter, randomized, 8-week, double-blind, placebo-controlled study followed by a 6-month open-label extension to evaluate the efficacy and safety of DVS SR [desvenlafaxine sustained-release] in peri- and postmenopausal women with major depressive disorder.

Trial Profile

A multicenter, randomized, 8-week, double-blind, placebo-controlled study followed by a 6-month open-label extension to evaluate the efficacy and safety of DVS SR [desvenlafaxine sustained-release] in peri- and postmenopausal women with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2012

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder; Menopause
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 04 May 2012 Actual patient number changed from 387 to 381 as reported by ClinicalTrials.gov.
    • 28 Jul 2008 Status changed from in progress tp completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 Status changed from recruiting to in progress according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top